{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-sample-labeling-anonymization-pseudonymization”
},
“headline”: “SOP for Sample Labeling, Anonymization/Pseudonymization”,
“description”: “This SOP defines standardized procedures for labeling, anonymization, and pseudonymization of biological samples in clinical trials, ensuring confidentiality, integrity, and compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 24/12/2025
Standard Operating Procedure for Sample Labeling, Anonymization/Pseudonymization
| SOP No. | CR/OPS/083/2025 |
| Supersedes | NA |
| Page No. | 1 of 38 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to define a standardized procedure for labeling, anonymizing, and pseudonymizing biological samples collected during clinical trials. This ensures confidentiality of subject identity, integrity of sample tracking, and compliance with ICH GCP
Scope
This SOP applies to investigators, laboratory personnel, CROs, and sponsors involved in handling biological samples during clinical trials. It covers labeling procedures, coding conventions, anonymization methods, pseudonymization tracking, and related documentation.
Responsibilities
- Investigator: Ensures subject identity is protected in sample labeling.
- Clinical Staff: Label samples accurately and contemporaneously at the point of collection.
- Laboratory Personnel: Verify and maintain sample coding and tracking.
- CRA: Review sample labeling logs during monitoring visits.
- QA: Audit anonymization/pseudonymization practices for compliance.
Accountability
The Principal Investigator (PI) is accountable for correct and compliant sample labeling. The Sponsor is accountable for ensuring compliance with global privacy and data protection laws.
Procedure
1. Sample Labeling
1.1 Each sample must be labeled immediately upon collection.
1.2 Labels must include subject ID, sample type, date, and time of collection.
1.3 Subject identifiers (name, DOB, address) must never appear on sample labels.
1.4 Use pre-printed barcoded labels whenever possible.
1.5 Maintain Sample Labeling Log (Annexure-1).
2. Anonymization
2.1 Anonymization is the irreversible removal of personal identifiers.
2.2 Apply anonymization to genetic and long-term stored samples as required by protocol/regulation.
2.3 Document anonymization in Anonymization Log (Annexure-2).
3. Pseudonymization
3.1 Pseudonymization is the replacement of personal identifiers with codes, while a key exists separately.
3.2 Maintain Pseudonymization Key securely in Sponsor-controlled files.
3.3 Access to key is restricted to authorized personnel only.
3.4 Document pseudonymization in Pseudonymization Log (Annexure-3).
4. Verification and Tracking
4.1 Laboratory staff must verify label accuracy before processing.
4.2 Chain of custody records must link pseudonymized/anonymized codes to sample logs.
4.3 Deviations (e.g., mislabeling) must be recorded in Labeling Deviation Log (Annexure-4).
5. Confidentiality
5.1 All sample codes must be treated as confidential identifiers.
5.2 Unauthorized disclosure of keys is a major protocol deviation.
5.3 Ensure compliance with GDPR/HIPAA when sharing coded data internationally.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- CRA: Clinical Research Associate
- QA: Quality Assurance
- GDPR: General Data Protection Regulation
- HIPAA: Health Insurance Portability and Accountability Act
- CRO: Contract Research Organization
Documents
- Sample Labeling Log (Annexure-1)
- Anonymization Log (Annexure-2)
- Pseudonymization Log (Annexure-3)
- Labeling Deviation Log (Annexure-4)
References
- ICH E6(R2/R3) – Clinical Trial Essential Documents
- GDPR – Data Protection Rules
- HIPAA – US Data Privacy Law
- EMA – Biospecimen Privacy and Labeling
- CDSCO – Sample Management Regulations
- WHO – Guidance on Sample Confidentiality
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, Clinical Coordinator |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Sample Labeling Log
| Subject ID | Sample Type | Label Applied | Date/Time | By |
|---|---|---|---|---|
| SUBJ-201 | Blood | BL-201 | 15/09/2025 09:20 | Meena Sharma |
Annexure-2: Anonymization Log
| Date | Sample ID | Action | Performed By | Verified By |
|---|---|---|---|---|
| 16/09/2025 | GEN-001 | Identifiers removed | Lab Tech | QA Officer |
Annexure-3: Pseudonymization Log
| Subject ID | Pseudonym Code | Date Assigned | Responsible |
|---|---|---|---|
| SUBJ-202 | PS-202 | 16/09/2025 | Data Manager |
Annexure-4: Labeling Deviation Log
| Date | Sample ID | Deviation | Action Taken | Responsible |
|---|---|---|---|---|
| 17/09/2025 | BL-201 | Incorrect label placed | Relabeled, documented | Lab Tech |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Quality |
For more SOPs visit: Pharma SOP